How to Transition From Warfarin to a DOAC (Apixaban, Rivaroxaban, Edoxaban)

You've decided a patient is a good candidate to come off warfarin and onto a DOAC. The tricky part is the handoff, keeping them anticoagulated the whole way through without overshooting into a bleed. Here's how to do it cleanly.

If you want the warfarin side first, start with warfarin basics and dose adjustments, then come back here for the switch.

The goal

Keep anticoagulation stable during the changeover while minimizing bleeding and clotting risk.

Before you switch: a quick safety checklist

• Confirm the indication (AF vs. VTE treatment/secondary prevention vs. postop prophylaxis).
• Kidney function: check eGFR/CrCl. Apixaban is often preferred in CKD and can be used in ESRD or on dialysis per label and major guidelines. Avoid rivaroxaban and edoxaban with severe renal impairment per labeling.
• Liver disease: avoid DOACs in significant hepatic impairment, for example Child-Pugh C.
• Pregnancy or lactation: warfarin and DOACs are not preferred. Consult specialists.
• Drug interactions: review CYP3A4 and P-gp inducers and inhibitors, such as azoles, macrolides, rifampin, anticonvulsants, HIV meds, and St. John's wort.
• Insurance and cost: many manufacturers offer starter packs or copay support. Check patient assistance sites.

When to start the DOAC after stopping warfarin

Warfarin's effect lingers for days. Stop warfarin, follow the INR, and start the DOAC when the INR falls to the product-specific threshold:

• Apixaban (Eliquis): start when INR is less than or equal to 2.0
• Dabigatran: start when INR is less than 2.0
• Edoxaban: start when INR is less than or equal to 2.5
• Rivaroxaban (Xarelto): start when INR is less than or equal to 3.0

If you can't check the INR, a pragmatic approach is to hold warfarin for 2 to 3 days, then start the DOAC. Use clinical judgment and confirm with an INR as soon as you can.

No overlap or bridging is needed when switching from warfarin to a DOAC if you use the INR thresholds above.

Which DOAC? A quick take

• Apixaban: BID dosing, strong data across the CKD spectrum, and a lower GI bleed signal vs. some comparators in older adults.
• Rivaroxaban: once-daily maintenance for AF/VTE after the initial VTE phase. Avoid in severe CKD.
• Edoxaban: once daily after 5 to 10 days of parenteral anticoagulation for acute VTE. Watch for reduced efficacy at CrCl greater than 95 mL/min in AF.

I often choose apixaban in CKD or frail patients for the dosing flexibility and the evidence base.

Apixaban (Eliquis) dosing: quick reference

Always verify renal and hepatic status and check interactions before prescribing.

Practical tips for a smooth transition

• Write it down for the patient: "Stop warfarin today. Check INR on ___. Start Eliquis 5 mg BID when INR is 2.0 or below, and take the first dose that evening."
• No routine lab monitoring is required with DOACs, but periodic renal and hepatic checks are wise, at least annually and more often in CKD or older patients.
• Missed DOAC dose: take it as soon as remembered the same day and do not double up. Follow product-specific instructions.
• High bleeding risk or urgent procedures: know your local reversal pathways, for example andexanet alfa for apixaban and rivaroxaban, or 4-factor PCC as an alternative per protocol.

Cost and access

DOACs can be pricey. Try:

• Manufacturer copay cards and patient assistance programs
• Medicare Part D tier exceptions
• Pharmacy discount programs, and starter packs when available

Patient message template you can paste into the portal

We're changing from warfarin to Eliquis to simplify your anticoagulation. Stop warfarin today. We'll start Eliquis when your INR is 2.0 or below. Your Eliquis dose will be __ mg twice daily. Keep all other meds the same unless we message you. Call for bleeding, black stools, severe headache, or new shortness of breath or chest pain. Avoid new over-the-counter or herbal meds without checking with us.

References

• FDA Prescribing Information: apixaban (Eliquis), rivaroxaban (Xarelto), edoxaban (Savaysa/Lixiana).
• AHA/ACC/HRS guideline for AF anticoagulation; ASH and CHEST guidance for VTE management and DOAC use.
• ISTH guidance on DOACs in special populations (CKD, extremes of weight).
• Local health-system protocols for anticoagulant reversal and peri-procedural management.

Frequently asked questions

Do I need to bridge with heparin when going from warfarin to a DOAC?
No. If you wait for the INR to reach the product-specific threshold before starting the DOAC, no bridging is needed.

What if I can't get an INR before starting?
A pragmatic option is to hold warfarin for 2 to 3 days, then start the DOAC, using clinical judgment. Confirm with an INR as soon as you can.

How do I pick between apixaban, rivaroxaban, and edoxaban?
Renal function, dosing preference, and bleeding risk drive it. Apixaban is a common choice in CKD or frail patients. Avoid rivaroxaban and edoxaban in severe renal impairment.

The whole transition comes down to one rule: wait for the INR threshold, then start the DOAC, no bridging. For a one-page version you can keep open, the Clinical Desk Reference has the thresholds and apixaban dosing, and the Primary Care Clinical Mastery Program covers anticoagulation in depth. For the warfarin side, see warfarin basics and dose adjustments.

Education only. Use clinical judgment and your local guidelines.

Written by Allison Sowders, MSN, APRN, FNP-BC, a practicing primary care nurse practitioner and founder of Nurse Practitioner Mentor. Reviewed July 2026.